Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2495)	4/28/2009 2:54:17 PM
From: Jibacoa	Read Replies (2) \| Respond to of 3722

AVNR is also down 20.21% on profit taking after the recent spike. Volume of 141,617 is above its ADV but much less than the 690,000 traded yesterday.<g> bigcharts.marketwatch.com Bernard

To: Jibacoa who wrote (2495)	4/29/2009 3:01:05 PM
From: Jibacoa	Respond to of 3722

DCGN is down another 26.86% today with volume of 2,688,273 already above yesterday's. <g> The stock opened with a DG after it announced last night that it had received a letter from the NAZ'Council calling for review the April 22 determination of its listing qualifications. The stock will continue to trade on the Nasdaq Capital Market during the review process. <g> It seems that the stock will erase completely its Apr23 spike.<g> bigcharts.marketwatch.com Bernard

To: Jibacoa who wrote (2495)	6/25/2009 1:16:13 PM
From: Jibacoa	Respond to of 3722

BMY is up only 3.47% and volume remains moderate at less than half its ADV It announced that its marketing authorization application for ONGLYZA received a positive opinion from the CHMP for the treatment of type 2 diabetes in adults as add-on therapy with metformin, a thiazolidinedione or a sulphonylurea. The positive opinion was reached after the CHMP reviewed data from a clinical development program that included six PIIIs assessing the safety and efficacy of saxagliptin as a once-daily therapy in 4,148 patients with type 2 diabetes, including 3,021 patients treated with saxagliptin. The stock needs to close above $21 before it can test the Apr2 H at $22.22 The Feb 6 H at $23.78 seems like a more important resistance. <g> bigcharts.marketwatch.com YHOO's analyst consensus 'target' is $23.27 bigcharts.marketwatch.com Bernard